Identification

Summary

Modified vaccinia ankara is a live, non-replicating orthopoxvirus vaccine used to prevent smallpox, monkeypox, and other diseases caused by vaccinia virus.

Brand Names
Jynneos
Generic Name
Modified vaccinia ankara
DrugBank Accession Number
DB15483
Background

Modified Vaccinia Ankara (MVA) refers to an attenuated strain of the Vaccinia virus. Vaccines using MVA are live and non-replicating, and are produced using Modified Vaccinia Ankara-Bavarian Nordic (MVA-BN).2,3

Type
Biotech
Groups
Approved
Biologic Classification
Vaccines
Attenuated
Synonyms
  • Modified Vaccinia Virus (Ankara-Bavarian Nordic)
  • MVA
  • MVA-BN
  • Vaccinia strain modified ankara

Pharmacology

Indication

Modified vaccinia ankara is a vaccine indicated for the prevention of smallpox and monkeypox disease in adults 18 years of age and older determined to be at high risk for smallpox or monkeypox infection.1 In the EU, it is additionally indicated for the prevention of other diseases caused by the vaccinia virus.3

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Associated Conditions
Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug events
Improve clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events & improve clinical decision support.
Learn more
Pharmacodynamics

Not Available

Mechanism of action

Vaccination with Modified Vaccinia Ankara elicits humoral and cellular immune responses to orthopoxviruses, thereby providing host protection against future orthopoxvirus infections.1

Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.
Learn more
Improve decision support & research outcomes with our structured adverse effects data.
Learn more
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AbataceptThe therapeutic efficacy of Modified vaccinia ankara can be decreased when used in combination with Abatacept.
AdalimumabThe therapeutic efficacy of Modified vaccinia ankara can be decreased when used in combination with Adalimumab.
AldesleukinThe therapeutic efficacy of Modified vaccinia ankara can be decreased when used in combination with Aldesleukin.
AlefaceptThe therapeutic efficacy of Modified vaccinia ankara can be decreased when used in combination with Alefacept.
AlemtuzumabThe therapeutic efficacy of Modified vaccinia ankara can be decreased when used in combination with Alemtuzumab.
AltretamineThe therapeutic efficacy of Modified vaccinia ankara can be decreased when used in combination with Altretamine.
AmsacrineThe therapeutic efficacy of Modified vaccinia ankara can be decreased when used in combination with Amsacrine.
AnakinraThe therapeutic efficacy of Modified vaccinia ankara can be decreased when used in combination with Anakinra.
Antilymphocyte immunoglobulin (horse)The therapeutic efficacy of Modified vaccinia ankara can be decreased when used in combination with Antilymphocyte immunoglobulin (horse).
Antithymocyte immunoglobulin (rabbit)The therapeutic efficacy of Modified vaccinia ankara can be decreased when used in combination with Antithymocyte immunoglobulin (rabbit).
Identify potential medication risks
Easily compare up to 40 drugs with our drug interaction checker.
Get severity rating, description, and management advice.
Learn more
Food Interactions
Not Available

Products

Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
Brand Name Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing EndRegionImage
ImvamuneSuspension50000000 CCID50 / 0.5 mLSubcutaneousBavarian Nordic As2015-06-15Not applicableCanada flag
ImvanexInjection, suspension50000000 Inf. USubcutaneousBavarian Nordic A/S2020-12-18Not applicableEU flag
JynneosInjection, suspension50000000 1/0.5mLSubcutaneousBavarian Nordic A/S2021-03-17Not applicableUS flag
MvabeaInjection, suspension70000000 Inf. UIntramuscularJanssen Cilag International Nv2021-02-11Not applicableEU flag

Categories

Drug Categories
Classification
Not classified
Affected organisms
  • Humans and other mammals

Chemical Identifiers

UNII
TU8J357395
CAS number
Not Available

References

General References
  1. DailyMed Label: JYNNEOS (Smallpox and Monkeypox Vaccine, Live, Non-replicating) suspension for subcutaneous injection [Link]
  2. FDA Approved Drug Products: Jynneos (smallpox and monkeypox vaccine, live, non-replicating) for suspension for subcutaneous injection [Link]
  3. EMA Summary of Product Characteristics: Imvanex (Smallpox and monkeypox vaccine (Live Modified Vaccinia Virus Ankara)) for subcutaneous injection [Link]
  4. Health Canada Product Monograph: IMVAMUNE (modified vaccinia ankara) injection [Link]
RxNav
1668221

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
4CompletedPreventionVaccinations1
3Active Not RecruitingPreventionEbolavirus Disease1
3Active Not RecruitingPreventionMonkeypox Virus Infection1
3CompletedPrevention18-42 Year Old Healthy Vaccinia-naïve Subjects1
3CompletedPreventionEbola1
3CompletedPreventionHealthy Subjects (HS)2
3CompletedPreventionHemorrhagic Fever, Ebola1
3CompletedPreventionVariola Major (Smallpox)2
3RecruitingPreventionInfections, Respiratory Syncytial Virus1
2Active Not RecruitingPreventionEbolavirus Disease1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
SuspensionSubcutaneous50000000 CCID50 / 0.5 mL
Injection, suspensionSubcutaneous50000000 U.inf.
Injection, suspensionSubcutaneous50000000 Inf. U
Injection, suspensionSubcutaneous50000000 1/0.5mL
Injection, suspensionIntramuscular0.5 ML
Injection, suspensionIntramuscular70000000 Inf. U
Prices
Not Available
Patents
Not Available

Properties

State
Liquid
Experimental Properties
Not Available

Drug created at August 30, 2019 17:59 / Updated at August 04, 2022 21:49